EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
Conditions
Keywords
Cytotoxic T cell, Lymphoma, Immuno-oncology, ENKL, EBViNT, Gastric cancer, solid tumor, Esophageal AdenoCarcinoma
Brief summary
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive malignancies The present study investigates with 5 parts; Part1-phase I: IP single therapy on ENKL and solid tumors Part2-phase I: IP + lymphodepletion on solid tumors Part 3&5- Phase IIa: IP single therapy on each ENKL and solid tumors Part 4- Phase IIa: IP + lymphodepletion on solid tumors
Detailed description
The present study is a multi-center, single-arm, open, phase I/IIa clinical trial to evaluate the efficacy and safety of EBViNT Cell when administered to patients with Epstein-Barr (EBV) positive tumors After proving the safety through Part 1 and part 2, the efficacy and safety would be studied through part 3\ 5. * If CTCAE grade 3 or higher adverse drug events (ADR) do not occur in the three subjects: Begin enrollment for phase IIa * If a CTCAE grade 3 or higher ADR occurs in one of the three subjects: Enroll three more subjects (up to six subjects in total) and assess whether any CTCAE grade 3 or higher ADR occurs * If a CTCAE grade 3 or higher ADR does not occur in the three additional subjects (1/6): Begin enrollment for phase IIa * If a CTCAE grade 3 or higher ADR occurs in at least one of the three additional subjects (more than 2/6): Begin enrollment for phase IIa at 7.0x10\^8 cells, the maximum dose from phase I * If a CTCAE grade 3 or higher ADR occurs in two of the three subjects: Begin enrollment for phase IIa at 7.0x10\^8 cells, the maximum dose from phase I Subjects participating in the present study will undergo 1) an EBV epitope screening test followed by 2) an eligibility assessment for clinical trial enrollment. Subjects who are administered with the investigational product will be monitored until progressive disease (PD) is confirmed or for 24 weeks (main observation period of 4 weeks + monitoring for 20 weeks) to evaluate the product's safety and efficacy, and will undergo immunological assessment. Radiological tests for tumor assessment will be conducted at the enrollment visit, 4 weeks, 8 weeks, 16 weeks, and 24 weeks and assessed by the Independent Radiology Review Committee (IRRC) using the Lugano criteria. To eliminate pseudo-progression, progressive disease (PD) will be determined by considering immunological tests, a quantitative EBV DNA assay, and intermediate response (IR) under LYRIC. Biopsies may be performed to achieve this.
Interventions
BIOLOGICALEBViNT Cell
1. Dosage: 1 bag containing 1.4x10\^9 cells/100mL 2. Administration: Inject intravenously over 30 minutes 3. Dosing schedule: Single dose
Sponsors
Eutilex
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
(Visit 1) 1. At least 19 years of age 2. Patients with lymphomas or solid tumors who have been found to be positive for EBV encoded RNA (EBER) by in situ hybridization (ISH) (previous test results may be used as evidence if available) 1. Part 1: Histologically or cytologically confirmed lymphoma or solid tumor 2. Part 2: Histologically or cytologically confirmed solid tumor 3. Part 3: Patients who have been diagnosed with histologically confirmed extranodal NK/T-cell lymphoma (ENKL) according to WHO classification 4. Parts 4 and 5: Patients with histologically confirmed gastric cancer or esophageal adenocarcinoma 3. Patients who have given written consent to voluntarily participate in the epitope screening
Exclusion criteria
(Visit 1) 1. Patients with aggressive NK cell leukemia 2. Patients with hemophagocytic lymphohistiocytosis (HLH) 3. Persons who have previously received a solid organ transplant 4. Persons who have been diagnosed with a malignant tumor other than the target disease in the past 5 years (treated basal cell carcinoma, squamous epithelial cell carcinoma, and non-invasive cervical cancer do not necessitate exclusion) 5. Patients in whom a tuberculosis infection was confirmed in the 1 year prior to screening for the present study (However, patients who have been determined to be cured after treatment may be enrolled.) 6. Patients who test positive for anti-HIV antibodies 7. Patients deemed unsuitable to participate in the clinical trial by an investigator based on active infection (HBV, HCV) test results Enrollment Criteria (Visit 2) 1. Persons who have been found to be capable of production in the epitope screening test 2. Patients who have failed standard treatment or conventional chemotherapy and who meet any one of the following 1. Patients who have relapsed/progressed after 1 or more chemotherapies, and for whom standard treatment does not exist or cannot be performed 2. Intolerable patients for whom anticancer treatment cannot be performed or a minimum of one full cycle cannot be completed in a first-line chemotherapy 3. Patients who are refractory to first-line chemotherapy 3. Persons with evaluable lesions 1. Lymphoma: Persons with at least 1 lesion with long axis \> 15 mm or 18FDG-PET-CT avid 2. Solid tumor: Persons with at least 1 measurable lesion based on RECIST 1.1 4. Persons with appropriate liver, renal, and bone marrow function (two retests are permitted for borderline results, and corrections such as transfusion are permitted)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Confirmed objective response rate (confirmed ORR) [assessed by IRRC] | up to 6 month from LPI |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS) | up to 6 month from LPI |
| Overall survival (OS) | up to 6 month from LPI |
| Objective response rate (ORR) [assessed by investigator] | up to 6 month from LPI |
| Duration of response (DoR) [assessed by IRRC and investigator] | up to 6 month from LPI |
| Disease control rate (DCR) [assessed by IRRC and investigator] | up to 6 month from LPI |
| Partial response duration (PR duration) [assessed by IRRC and investigator] | up to 6 month from LPI |
| Complete response rate (CR rate) [assessed by IRRC and investigator] | up to 6 month from LPI |
| Partial response rate (PR rate) [assessed by IRRC and investigator] | up to 6 month from LPI |
Other
| Measure | Time frame | Description |
|---|---|---|
| Quantitative EBV DNA assay | up to 6 month | — |
| Immunological assessment | up to 6 month | Plasma cytokine analysis (IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-γ, IL-17a) EBV LMP2a-specific cytokine production (IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-γ, IL-17a) Phenotypical analysis of CD8 T cells |
Countries
South Korea
Contacts
Primary ContactSehee Hwang
Outcome results
None listed